Downregulation of VRK1 Inhibits Progression of Lung Squamous Cell Carcinoma through DNA Damage
出版年份 2023 全文链接
标题
Downregulation of VRK1 Inhibits Progression of Lung Squamous Cell Carcinoma through DNA Damage
作者
关键词
-
出版物
Canadian Respiratory Journal
Volume 2023, Issue -, Pages 1-12
出版商
Hindawi Limited
发表日期
2023-07-29
DOI
10.1155/2023/4533504
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- DNA damage response and repair in the development and treatment of brain tumors
- (2022) Parisa Maleki Dana et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Dual‐Loaded Liposomes Tagged with Hyaluronic Acid Have Synergistic Effects in Triple‐Negative Breast Cancer
- (2022) Shiyan Dong et al. Small
- GNA13 promotes the proliferation and migration of lung squamous cell carcinoma cells through regulating the PI3K/AKT signaling pathway
- (2022) Jianrong Na et al. TISSUE & CELL
- Identification of a DNA damage repair gene‐related signature for lung squamous cell carcinoma prognosis
- (2022) Bin Jia et al. Thoracic Cancer
- Elevated BTG2 improves the radiosensitivity of non‐small cell lung cancer ( NSCLC ) through apoptosis
- (2022) Changchun Zhu et al. Thoracic Cancer
- Identification of a DNA Damage Response and Repair-Related Gene-Pair Signature for Prognosis Stratification Analysis in Hepatocellular Carcinoma
- (2022) Yi Chen et al. Frontiers in Pharmacology
- VRK1 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis In Vitro and In Vivo
- (2022) Jiacheng Wu et al. Frontiers in Pharmacology
- The human VRK1 chromatin kinase in cancer biology
- (2021) Ignacio Campillo-Marcos et al. CANCER LETTERS
- DNA Aptamers against Vaccinia-Related Kinase (VRK) 1 Block Proliferation in MCF7 Breast Cancer Cells
- (2021) Rebeca Carrión-Marchante et al. Pharmaceuticals
- HNRNP A1 Promotes Lung Cancer Cell Proliferation by Modulating VRK1 Translation
- (2021) Hye Guk Ryu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Circular RNA VRK1 correlates with favourable prognosis, inhibits cell proliferation but promotes apoptosis in breast cancer
- (2020) Yang Li et al. JOURNAL OF CLINICAL LABORATORY ANALYSIS
- Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy
- (2020) Josephine Hai et al. CLINICAL CANCER RESEARCH
- Metal ions modify DNA-protecting and mutagen-scavenging capacities of the AV-153 1,4-dihydropyridine
- (2019) Elina Leonova et al. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
- Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
- (2019) Narjust Duma et al. MAYO CLINIC PROCEEDINGS
- High expression of VRK1 is related to poor prognosis in glioma
- (2018) Zhiyun Ben et al. PATHOLOGY RESEARCH AND PRACTICE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Overexpression of the VRK1 kinase, which is associated with breast cancer, induces a mesenchymal to epithelial transition in mammary epithelial cells
- (2018) Aye M. Mon et al. PLoS One
- VRK1 promotes cisplatin resistance by up-regulating c-MYC via c-Jun activation and serves as a therapeutic target in esophageal squamous cell carcinoma
- (2017) Zhen-Chuan Liu et al. Oncotarget
- Structural characterization of human Vaccinia-Related Kinases (VRK) bound to small-molecule inhibitors identifies different P-loop conformations
- (2017) Rafael M. Couñago et al. Scientific Reports
- Expression of vaccinia-related kinase 1 (VRK1) accelerates cell proliferation but overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma
- (2016) Jing Liu et al. Hematology
- Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities
- (2012) P. Perez-Moreno et al. CLINICAL CANCER RESEARCH
- Doxorubicin: The Good, the Bad and the Ugly Effect
- (2009) Cristina Carvalho et al. CURRENT MEDICINAL CHEMISTRY
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started